Global(EN)
Sinovac Passes China’s Ministry of Science and Technology “Pandemic Influenza Vaccine R&D Project” Examination
Beijing China--(CCNMatthews)--Nov. 14, 2005--Sinovac Biotech Ltd. (AMEX: SVA - News) announced that it the Chinese Ministry of Science and Technology (MoST) has examined its Pandemic Influenza Vaccine R&D Project and accepted the results; clearing the way for continued sponsorship of the program.
China’s MoST periodically evaluates the nationally funded Pandemic Influenza Vaccine R&D Project, and determines if sufficient progress has been made before Sinovac is permitted to continue. For the first critical step, top professionals from MoST conducted extensive evaluations of Sinovac’s preclinical trials, and accepted all the results of this project to date. Top professionals from MoST determined that Sinovac’s method for developing an avian influenza vaccine for humans can be used for the prevention of influenza pandemic among humans, caused by the mutated strain from H5N1. Sinovac established in its preclinical trials that it has the ideal technological platform, personnel, equipment and management for the vaccine’s development and production. Sinovac’s preclinical trials have shown that its vaccine candidate has a high-quality safety and immunogenicity profile.
Sinovac developed its proprietary Pandemic Influenza Vaccine based on the NIBRG-14 virus strain provided by the British National Institute of Biological Standards and Control (NIBSC). Since April 2004, Sinovac completed its study of production processes; established a viral “seed bank” for vaccine production; and set up quality standards and testing methods.
Sinovac has applied for human clinical trials for its pandemic influenza vaccine with the Chinese State Food and Drug Administration (SFDA). In preparation for approval, Sinovac has already produced sufficient pandemic flu vaccines to complete human clinical trials.
Successful vaccine research and development of a Pandemic influenza vaccine is Sinovac’s second national achievement against emerging virulent infectious diseases. In 2004 Sinovac developed a safe and effective inactivated SARS vaccine, and became the first company in the world to successfully complete phase I clinical trials.
About Sinovac
Sinovac Biotech Ltd. is a world leader in the research, development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and avian influenza (bird flu). The Company's objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in
Additional information about Sinovac is available on the Company website, http://www.sinovac.com
For additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "
SOURCE: Sinovac Biotech Ltd.
CONTACT:
Craig H. Bird
Investor Relations
(215) 782 - 8682
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
